| Thomas Bateman, | |
|
3601 S 6th Ave, Tucson, AZ 85723-0001 | |
| (520) 792-1450 | |
| Not Available |
| Full Name | Thomas Bateman |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 6 Years |
| Location | 3601 S 6th Ave, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396235875 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | PENDING (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Services Of Southern Arizona | 0345568424 | 2 |
News Archive
Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.
About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
In the wake of Queensland's devastating floods there are warnings to residents, volunteers and others regarding protection against diseases. Australian Medical Association Queensland president-elect Dr Richard Kidd said he expected a number of diseases to appear as a result of people coming in contact with floodwaters and especially the mud left behind.
› Verified 6 days ago
| Entity Name | Bisbee Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518968767 PECOS PAC ID: 5092626168 Enrollment ID: O20040623001007 |
News Archive
Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.
About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
In the wake of Queensland's devastating floods there are warnings to residents, volunteers and others regarding protection against diseases. Australian Medical Association Queensland president-elect Dr Richard Kidd said he expected a number of diseases to appear as a result of people coming in contact with floodwaters and especially the mud left behind.
› Verified 6 days ago
| Entity Name | Medical Services Of Southern Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871985366 PECOS PAC ID: 0345568424 Enrollment ID: O20150422000540 |
News Archive
Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.
About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
In the wake of Queensland's devastating floods there are warnings to residents, volunteers and others regarding protection against diseases. Australian Medical Association Queensland president-elect Dr Richard Kidd said he expected a number of diseases to appear as a result of people coming in contact with floodwaters and especially the mud left behind.
› Verified 6 days ago
| Entity Name | Anesthesia Partners & Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336530997 PECOS PAC ID: 9931429198 Enrollment ID: O20150529000706 |
News Archive
Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.
About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
In the wake of Queensland's devastating floods there are warnings to residents, volunteers and others regarding protection against diseases. Australian Medical Association Queensland president-elect Dr Richard Kidd said he expected a number of diseases to appear as a result of people coming in contact with floodwaters and especially the mud left behind.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Bateman, 3453 Elkfield Cv, Memphis, TN 38135-3040 Ph: () - | Thomas Bateman, 3601 S 6th Ave, Tucson, AZ 85723-0001 Ph: (520) 792-1450 |
News Archive
Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.
About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
In the wake of Queensland's devastating floods there are warnings to residents, volunteers and others regarding protection against diseases. Australian Medical Association Queensland president-elect Dr Richard Kidd said he expected a number of diseases to appear as a result of people coming in contact with floodwaters and especially the mud left behind.
› Verified 6 days ago
Steven Anderson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1625 N Campbell Ave, Tucson, AZ 85719 Phone: 520-827-8448 | |
Silvia Galvan Druke, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave Rm 5301, Tucson, AZ 85724 Phone: 520-626-7221 Fax: 520-626-6943 | |
Brigette Vyborny, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave, Tucson, AZ 85724 Phone: 420-694-0111 | |
Kimberly K Vinayak, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 3601 S 6th Ave, Tucson, AZ 85723 Phone: 520-792-1450 | |
Kitra Henker, RN Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1625 N Campbell Ave, Tucson, AZ 85719 Phone: 520-694-1100 | |
Melissa Schwarzenberger, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: Banner University Medical Center 1501 N Campbell Avenue, Tucson, AZ 85724 Phone: 520-694-0111 | |
Alysia Reina, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave, Tucson, AZ 85724 Phone: -- |